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Abstract 
Purpose 
To investigate differences in prostate cancer incidence between two distinct Swiss regions from 
1996 to 2013 stratified by age group, grade and T-stage. 
 
Methods 
The dataset included 17,495 men living in Zurich and 3,505 men living in Ticino, diagnosed 
with prostate cancer between 1996 and 2013. We computed age-standardized incidence rates 
per 100,000 person-years using the European Standard Population. Trends were assessed using 
JoinPoint regression analysis Software. 
 
Results 
Age-standardized incidence rates were generally higher in Zurich compared to Ticino but the 
difference decreased over time. Incidence rates increased significantly up to 2002 in Zurich and 
2007 in Ticino and then decreased. A statistically significant increase was observed for men 
aged <65 years, for grade 3 tumors, and for T-stage 2 and 3 tumors. The largest decrease was 
seen for grade 1 tumors. Furthermore, the incidence of tumors of unknown grade or T-stage 
decreased significantly in both regions. 
 
Conclusions 
The trends in prostate cancer incidence rates were similar in both regions, although on a higher 
level in Zurich compared to Ticino. However, the difference decreased over time. The 
distribution of T-stage and grade did not explain the difference in incidence rates. Different use 
of opportunistic screening may play a role. 
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Introduction 
As in many Western countries, prostate cancer is the most common cancer among men in 
Switzerland [1]. However, differences in prostate cancer incidence and mortality have been 
observed between the German-speaking and the Italian-speaking part of Switzerland [2,3]: 
Age-standardized incidence rates were 124/100,000 person-years in the German-speaking and 
96/100,000 person-years in the Italian-speaking part between 2009 and 2013, age-standardized 
mortality rates were 24/100,000 person-years in the German-speaking and 18/100,000 person-
years in the Italian-speaking part during the same time period [4]. The reasons for these 
differences are unclear. Cross-sectional data from the Swiss Health Surveys propose some 
differences in lifestyle habits potentially associated with risk of prostate cancer between men 
living in the German-speaking and the Italian-speaking part [5]. For example, living in the 
Italian region was associated with "risk-reducing" diet, such as lower consumption of dairy 
products and meat and high fish consumption [5]. However, other potentially protective 
behaviors were more common in the German-speaking part (e.g. physical activity, vegetable 
consumption, low alcohol consumption) [5]. 
There is no organized prostate cancer screening program in Switzerland, but opportunistic 
screening is frequent and often recommended to men aged 50 years and older by their 
physicians or urologists [6]. Differences in screening practices may also explain some of the 
differences in prostate cancer incidence observed in Zurich and Ticino. To further address these 
differences, we examined incidence trends from 1996 to 2013 by age group, grade and T-stage 
using data from the cantonal cancer registries of Zurich (German-speaking part) and Ticino 
(Italian-speaking part). 
 
Methods 
Data 
The collection of cancer registry data is not yet mandatory in Switzerland, however, several 
regions have set up cantonal cancer registries starting in the 1970s. The cancer registry of the 
cantons of Zurich and Zug is the largest Swiss registry covering a population of roughly 1.6 
million inhabitants. The registry for Zurich was established in 1980, the one for Zug in 2011. 
The cancer registry of the canton of Ticino was established in 1996 and covers a population of 
about 350’000 inhabitants. To be included in a canton’s cancer registry a patient has to live in 
the respective canton, even if they are treated in another canton. In order to be comparable, 
incidence data from 1996 to 2013 were included for both cantons. 
The dataset includes data on date of diagnosis, basis of diagnosis (death certificate only (DCO), 
clinical, clinical investigation, specific tumor markers, cytology, histology of metastasis, 
histology of primary tumor, unknown), age at diagnosis, tumor grade, as well as T-stage. 
The dataset for the canton of Zurich included 17,535 men who were diagnosed with prostate 
cancer (C61.9 ICD-O, 3rd edition) between 1996 and 2013 and lived in the canton of Zurich. 
Patients with unknown basis of diagnosis (n=2), or with a histology of metastasis as basis of 
diagnosis (n=38) were excluded, resulting in a final dataset of 17,495 men. The dataset for the 
canton of Ticino included 3536 men who were diagnosed with prostate cancer between 1996 
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and 2013 and lived in the canton of Ticino. Patients with unknown basis of diagnosis (n=1) and 
with a histology of metastasis as basis of diagnosis (n=30) were excluded, resulting in a final 
dataset of 3505 men. 
For Zurich, the percentage of death certificate only cases (DCO) was 2.3% for the period 1996–
2013 and the percentage of morphologically verified cases (MV) 93.0%. For Ticino, the 
percentage of DCO cases was 1.5% and the percentage of MV cases 91.1%. 
 
Statistical analyses 
Age-standardized incidence rates per 100,000 person-years were computed using the 1976 
European Standard Population [7] and mid-year population estimates. For age-stratified 
analyses, we used three age groups: <65 years, 65-74 years, and ≥75 years. Because the 
corresponding Gleason Score (GS) is often missing in our data, we used tumor grade instead of 
GS. Grade was defined as grade 1 (well differentiated), grade 2 (moderately differentiated), 
grade 3 (poorly differentiated), and unknown grade. T-stage (based on TNM) was stratified as 
T-stage 1, T-stage 2, T-stage 3, T-stage 4, and unknown T-stage. We chose pathological T-
stage if available, otherwise clinical T-stage. StataSE 14 (Stata Corporation, College Station, 
TX, USA) was used to prepare the incidence files by calendar year and age group/grade/T-
stage. 
Incidence time trends were assessed using joinpoint regression analysis (JoinPoint Trend 
Analysis Software Version 4.3.1.0, April 2016; US National Cancer Institute, Division of 
Cancer Control & Population Sciences, Surveillance Research Program). This method is used 
to determine the number of joinpoints that are adequate for assessing significant changes in 
incidence trends over time. The analysis starts with 0 joinpoints (corresponding to a straight 
regression line) and tests whether one or more joinpoints are significant. The Grid Search 
Method and the Monte Carlo permutation method with 4499 replicates and a significance level 
of 0.05 were used [8]. We defined the maximum number of joinpoints as three, the minimum 
number of observations from a joinpoint to either end of the data as three, and the minimum 
number of observations between two joinpoints as six (including any joinpoint that falls on an 
observation) [8]. The dependent variable was the age-standardized incidence rate, the 
independent variable was calendar year, and age category/grade/T-stage were defined as by-
variables. Model estimates included the number of joinpoints as well as the slopes and 
intercepts for each regression line between two joinpoints, in addition to the annual percentage 
change (APC) for each identified trend. Furthermore, the program provides average annual 
percentage changes (AAPC), a summary measure over the whole period of observations (1996-
2013). Log-transformation was used because of non-normality of the data. The AAPC are 
presented with 95% confidence intervals (95% CI). A joinpoint model was fit for overall 
prostate cancer incidence, then separate models were fit for subgroups by age, grade and T-
stage. 
 
5 
 
Results 
We included 17,495 and 3505 prostate cancer cases for the cantons of Zurich and Ticino, 
respectively (Table 1). Grade was unknown for 10.6% of the included cancer cases in Zurich 
and for 13.3% in Ticino; for T-stage percentages “unknown” were 28.5% for Zurich and 27.7% 
for Ticino. Fig. 1 shows the age-standardized incidence rates between 1996 and 2013 for Zurich 
and Ticino. The numbers and crude, age-standardized and age-stratified incidence rates are 
shown in Electronic Supplementary Material Table 1. In 1996, age-standardized incidence rates 
were almost 40% lower in Ticino compared to Zurich (76.9/100,000 versus 122.8/100,000) and 
thus, the increase observed in both cantons started on a much lower level in Ticino. According 
to joinpoint regression analysis, the age-standardized incidence rate increased between 1996 
and 2002 in Zurich (APC = 3.1, 95% CI 1.4, 5.0) and between 1996 and 2007 in Ticino (APC 
= 6.0, 95% CI 3.3, 8.8), indicating that the increase was steeper and lasted five years longer in 
Ticino. Consequently, the incidence rates in the two cantons were on a similar level in 2007 
(129.8/100,000 in Ticino versus 136.1/100,000 in Zurich). In Zurich, the incidence rate started 
to decrease in 2002 (APC = -1.3, 95% CI -2.3, -0.3) with a more pronounced decrease starting 
in 2011 (APC = -10.5, 95% CI -18.8, -1.2). In Ticino, the age-standardized incidence rate 
started to decrease in 2007 (APC = -5.2, 95% CI -10.1, -0.1). In 2013, the age-standardized 
incidence rate was about 20% lower in Ticino compared to Zurich (82.6/100,000 versus 
105.1/100,000). The detailed results from the joinpoint analyses, also stratified by age group, 
grade and T-stage, are displayed in Electronic Supplementary Material Table 2. 
 
Table 1. Prostate cancer cases reported for the cantons of Zurich and Ticino (Switzerland) between 1996 and 2013 
 Zurich Ticino 
 N % N % 
Total cases 17,495 100 3,505 100 
Age at diagnosis     
<65 years 5,005 28.6 899 25.7 
65-74 years 6,992 40.0 1,378 39.3 
≥75 years 5,498 31.4 1,228 35.0 
Grade     
1 1,524 8.7 167 4.8 
2 7,574 43.3 1,238 35.3 
3 6,547 37.4 1,632 46.6 
unknown 1,850 10.6 468 13.3 
T-stage     
1 4,325 24.7 386 11.0 
2 5,758 32.9 1,330 37.9 
3 2,107 12.0 725 20.7 
4 323 1.9 94 2.7 
unknown 4,982 28.5 970 27.7 
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Table 2 displays the AAPC for the separate joinpoint models according to canton, age group, 
grade, and T-stage. A significant overall increase was seen in the youngest age group (<65 
years) in both cantons and in the intermediate age group (65-74 years) in Ticino only, and a 
significant decrease in the oldest age group (≥75 years) in Zurich only (Fig. 2). Both tumors 
with unknown grade and with unknown T-stage decreased significantly in Zurich and Ticino 
between 1996 and 2013. The most pronounced overall decrease was observed for grade 1 
tumors in both cantons (Fig. 3), and this decrease was especially pronounced after 2003 
(Zurich) and 2002 (Ticino, Electronic Supplementary Material Table 2). AAPC was also 
negative for grade 2 tumors, although only significant for Zurich and mainly driven by a steep 
decrease starting in 2007. Grade 3 tumors increased significantly, however, in Ticino the 
increase in these tumors was interrupted in 2007 followed by a (non-significant) decrease. We 
observed significant overall increases for T-stage 1, 2 and 3 tumors in both cantons with most 
pronounced increases for T-stage 1 tumors. To some extent, the increase in T-stages 1-3 tumors 
was driven by the decrease in the proportion of unknown T-stage tumors. A decrease was 
observed in T-stage 4 tumors (Fig. 4), although only significant for Ticino. 
 
Table 2. Average annual percentage change (AAPC) and 95% confidence intervals (95% CI) stratified by age 
group, grade and T-stage based on joinpoint regression analysis, 1996-2013, Zurich and Ticino (Switzerland) 
 Zurich Ticino 
 AAPC 95% CI AAPC 95% CI 
overall -0.9 -2.1, 0.3 1.9 -0.4, 4.2 
<65 years 2.0 0.5, 3.5 5.5 1.0, 10.1 
65-74 years 0.3 -1.0, 1.7 2.4 0.3, 4.6 
≥75 years -3.8 -4.2, -3.3 -1.2 -2.5, 0.2 
Grade 1 -23.9 -27.7, -19.9 -19.7 -26.6, -12.0 
Grade 2 -4.8 -6.7, -2.9 -1.6 -3.5, 0.5 
Grade 3 8.3 6.8, 9.8 11.6 7.2, 16.3 
Grade unknown -4.2 -7.9, -0.4 -5.2 -9.2, -1.1 
T-stage 1 10.0 6.4, 13.7 19.2 4.9, 35.4 
T-stage 2 3.6 0.2, 7.1 8.0 3.6, 12.6 
T-stage 3 3.7 2.1, 5.3 2.6 0.0, 5.3 
T-stage 4 -2.3 -5.3, 0.9 -6.3 -9.4, -3.0 
T-stage unknown -14.7 -17.9, -11.3 -9.1 -12.4, -5.7 
AAPC, average annual percent change; 95% CI, 95% confidence interval 
 
When stratifying the analyses by age group and grade/T-stage simultaneously (data not shown), 
a significant decrease in grade 1 tumors with AAPC of about 20% in Zurich and 15% in Ticino 
was present in all three age groups. Grade 2 tumors decreased in both cantons mainly in the 
older age groups with no significant change in AAPC for men <65 years of age. The overall 
observed increase in grade 3 tumors was present in all three age groups and both cantons with 
larger AAPC in the two younger age groups. There was a tendency towards decrease in 
unknown grade tumors in all age groups and both cantons, although mostly not statistically 
significant. 
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A significant increase in T-stage 1 tumors was observed in all age groups and both cantons with 
highest AAPC of around 17% in the youngest age group in both Zurich and Ticino (data not 
shown). Similarly, T-stage 2 tumors increased in all age groups and both cantons, but the AAPC 
were in a smaller range and not significant for those ≥75 years in Zurich. A significant increase 
in T-stage 3 tumors was present in all age groups in Zurich, but in Ticino, a significant increase 
was only seen in the youngest age group. A significant decrease in T-stage 4 tumors was present 
in the youngest age group in Zurich and the intermediate age group in Ticino with no significant 
AAPC in the other age groups. Finally, the decrease in tumors of unknown T-stage was 
significant in all age groups except in the youngest age group in Ticino. The AAPC tended to 
be higher in Zurich compared to Ticino. 
 
 
Discussion 
In 1996, the incidence of prostate cancer was higher in Zurich (German-speaking part) 
compared to Ticino (Italian-speaking part), but at the end of observation in 2013, the difference 
between the two cantons was smaller. One explanation for the larger difference in 1996 may be 
that the cancer registry in Zurich started in 1980, while for the cancer registry Ticino 1996 was 
the first year of data registration, and under-reporting is typically observed right after the start 
of a Cancer Registry [9]. Despite the different starting levels, our analyses showed an overall 
similar time trend in both cantons with an increase in the early phase of the observed period 
and a decrease in the later phase. The increase in Ticino was steeper and went on until 2007, 
while in Zurich the trend from an increasing to a decreasing pattern occurred in 2002. The 
stratified analyses by age group, grade and T-stage did not reveal systematic differences 
between the two cantons, except for a different T-stage distribution with a higher proportion of 
T-stage 1 cancer cases in Zurich than in Ticino. This may reflect different opportunistic 
screening patterns. Another explanation for the observed stage migration with an increase in 
smaller tumors and a decrease in larger tumors may be a change in the number of prostate 
biopsies with extended pattern prostate biopsy templates resulting in the detection of smaller 
volume tumors [10]. In both cantons, incidence rates increased in the youngest age group, which 
may also be related to screening with prostate cancers being detected earlier in life. 
Besides screening, a difference in lifestyle factors associated with prostate cancer may partly 
explain the lower incidence rates in Ticino. There is evidence for a protective effect of low 
dairy product and meat consumption, and high fish, vegetable and fruit consumption on the risk 
of prostate cancer [11,12]. Furthermore, there seems to be a small inverse association between 
physical activity and prostate cancer risk [13]. Men living in the Italian-speaking part had a 
lower consumption of dairy products and meat and a higher fish consumption compared to men 
living in the German-speaking part [5], which may partly explain the lower incidence rates in 
Ticino. However, physical activity was higher in the German-speaking part [5]. 
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Comparison with other studies 
In a large evaluation of 43 populations worldwide [14], which also included data from the Swiss 
registries of Geneva and St. Gall-Appenzell, a moderate increase in prostate cancer incidence 
in these two Swiss registries between the 1980s and 2000 was observed, which was followed 
by a plateau. This was mostly similar across age groups, with the exception of a decrease in 
incidence rates in men ≥75 years of age starting at the end of the 1990s, whereas an increase 
was still observed in men 45-54 years old that started in the mid-1990s. In the 1990s, the 
increase in incidence was strongest in men 55-64 years old (APC 11.4%). This pattern was 
similar in another publication, which only included data from the Geneva cancer registry [15]. 
A more recent study on temporal patterns of prostate incidence and mortality in 36 countries 
showed an increase in the incidence of prostate cancer in Switzerland between 1998 and 2007 
[16], which is in line with our results. 
Comparing our data from the German-speaking part (Zurich) with data from Germany, which 
is similar regarding language and culture, a study based on data form the Cancer Registry 
Schleswig-Holstein reported an incidence rate of 106.1/100,000 in 1999-2005 [17]. Similar to 
the pattern in Zurich, incidence increased up to 2003 (from about 80/100,000 in 1999 to about 
130/100,000 in 2003) and decreased thereafter [17]. About 64% were grade 2 und 27% grade 
3 tumors [17] compared to 43% and 37% in Zurich, respectively. In a German study covering 
12 cancer registries (33% of the German population), a decrease in incidence rate between 1999 
and 2010 similar to our results was observed in men aged ≥75 years [18]. However, the largest 
increase in the German study was reported for men aged 65-74 years [18] while we observed 
no significant change in this age group and the largest increase in men under the age of 65 
years. 
Comparing our data from the Italian-speaking part (Ticino) with data from Italy (which is 
similar regarding language and culture), a study estimating trends in Italy reported a comparable 
pattern in incidence rates with around 60/100,000 in the mid-1990s increasing to just under 
100/100,000 in 2005 and decreasing thereafter [19]. Similar increasing trends up to 2005 were 
estimated for different regions in Italy [20]. Data from the Tuscany cancer registry in central 
Italy showed much higher incidence rates but a similar pattern, with an increase from about 
120/100,000 in 1985 to almost 290/100,000 in 2003 (APC =4.9, 95% CI 4.3, 5.4) and a non-
significant decrease thereafter (APC = -3.9, 95% CI -15.3, 8.9) [21]. 
The changes in prostate cancer incidence rates in Switzerland and other Western countries may 
be due to changes in prostate cancer screening behavior. In the United States, the US Food and 
Drug Administration (FDA) approved Prostate-specific Antigen (PSA) testing in 1986 as a 
means of monitoring prostate cancer progression, and ideally tumor detection, in conjunction 
with digital rectal exam (DRE) in men ≥50 years of age in 1994 [22]. The situation in 
Switzerland is different, as in 2011, the Swiss Medical Board advised against PSA testing for 
prostate cancer in men without symptoms or without a family history based on cost-benefit 
analyses [23]. However, opportunistic screening is frequent in Switzerland [6]. In an analysis 
of opportunistic prostate cancer screening use in Switzerland based on the Swiss Health Surveys 
between 1992 and 2012, the prevalence of ever use among men ≥50 years of age increased from 
55.3% in 1992 to 70.0% in 2012 [6]. The use of prostate cancer screening in the last two years 
before the respective survey increased from 32.6% to 42.4% [6]. Interestingly, until 2002, 
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participation was higher in the German-speaking part of Switzerland than in the Italian part 
(1992: 34.4% vs. 26.6% for prostate cancer examination in the last two years; 2002: 36.0 vs. 
34.4%), but in 2007 and 2012, participation in the German-speaking region was lower (41.4% 
vs. 46.6% and 40.7% vs. 48.5%, respectively). Thus, the increase in men having had a PSA test 
in the two years preceding the survey was larger in the Italian- than in the German-speaking 
region of Switzerland, which corresponds to a higher increase of T-stage 1 tumors in Ticino 
compared to Zurich during the observation period. 
 
Changes by stage 
Stage-specific changes in incidence rates have not yet been reported for Switzerland. In a 
Norwegian study covering 1980-2010, the incidence of prostate cancer increased, in particular 
in the period 2001 to 2010, i.e. after the introduction of PSA screening [24]. However, the 
changes differ by age and stage of the disease, such that in men 50-64 and 65-74 years old, the 
incidence of localized and regional tumors increased whereas that of distant tumors decreased, 
which is in line with our results. A Swedish study which evaluated cancer registry data between 
1996 and 2005 reported a rapid increase in the incidence of T1c tumors, whereas the incidence 
rates of T1a/T1b and T3/T4 tumors decreased slightly and T2 tumors increased moderately 
[25]. 
In a Dutch study, covering the period 1989-2006, incidence of cT1c tumors increased steadily 
since its introduction into the TNM system in 1993 [26]. This increase was most strongly seen 
in men younger than 74 years of age. In men ≥75 years of age, the incidence of cT1c cases 
increased slowly but steadily [26]. In a British study, an increase in prostate cancer incidence 
was reported between 2000 and 2010 for all age groups except for men >80 years of age [27]. 
Both localized and advanced tumor incidence increased, but the latter to a smaller extent. 
According to a German study, the proportion of localized tumors increased from 52% in the 
period 1998-2000 to 68% in 2007-2010, while the proportion of regional and distant tumors 
decreased from 31% to 23% and from 17% to 10%, respectively, in the same time period [18]. 
The Munich study reported increases in T-stage 1 and 2 tumors and a decrease in T-stage 4 
tumors, which is in line with our results, however a decrease in T-stage 3 tumors was observed 
in Munich while in Zurich we observed an increase in these tumors [28]. An Italian study 
reported a sharp increase in T-stage 1 tumors between the time period 1996-1999 and 2005-
2007 from 35% to 59% and a decrease in T-stage 3-4 tumors from 33% to 11% [29]. Another 
Italian study focusing on three regions reported an increase in localized tumors only in Varese, 
while these tumors remained stable in Genova and decreased in Modena between the mid-1980s 
and 1990s [30]. On the other hand, regional tumors increased in all three regions while distant 
tumors decreased [30]. 
 
Changes by grade 
The comparison with other studies regarding grade is not straightforward because most other 
studies used GS to define grade. The Swedish study observed that the vast majority of cases 
(55-65%) were those with a GS 5-6. Between 2000 and 2005, the incidence of GS 2-4 tumors 
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decreased, whereas GS 5-6 and GS 7 tumors increased. Only a slight increase was seen for GS 
8-10 [25]. In the British analyses, the incidence of GS ≤6 tumors decreased, while cases with 
GS ≥7 increased [27]. In the Dutch study [26], the number of well-differentiated tumors 
increased until 1995 and then decreased until 2003. A sharp increase was noted thereafter, 
which is very likely due to the Dutch Cancer Registries switching from the WHO grading 
system to the GS system around 2004. The Munich study also reported a decrease for GS 2-4 
and 5-6 tumors and a large increase in GS 7 tumors, while there was no change in GS 8-10 
tumors [28]. One of the Italian studies reported a decrease in GS 2-4 tumors (from 19% to 8%) 
but an increase in GS 5-6 tumors (from 39% to 52%), while GS 7 tumors increased only slightly 
and GS 8-10 tumors decreased only slightly [29]. 
Except for the Dutch study, most studies including the present study indicate a grade shift 
towards higher grading [25,28,27]. Several studies confirmed a trend towards higher grading 
such that pathologists have been shown to assign higher grades to the same tumors in the early 
2000s compared to the 1990s [31]. In 2005, the GS grading system was revised and adapted by 
the International Society of Urological Pathology in order to reflect changes in the detection of 
prostate cancer, including PSA screening, methods of obtaining prostate tissue, 
immunohistochemistry, etc. [32,33]. The detailed modifications in the GS system are 
summarized in Epstein et al. (2005) [33]. 
 
Strengths and limitations 
Strengths of the study are the relatively large sample size, the relatively long observation period 
(18 years) and the generally good quality of data collection in these two cantonal Swiss cancer 
registries as reflected by the low proportion of DCO cases and the high proportion of MV cases. 
However, T-stage and grade information are incomplete, but the percentage of cases with 
missing information decreased over time. The availability of either pathological or clinical T-
stage increased from 27.8% to 94.9% in Zurich and from 45.2% to 89.0% in Ticino between 
1996 and 2013. Grade was missing if only clinical data (and no pathological data) was available. 
Furthermore, stage and grade were sometimes not entered into the database due to limited 
resources, especially in earlier years. Finally, the sample size of our study did not allow for 
stratifying cancer stage into subcategories. 
 
Conclusions 
In 1996, the incidence of prostate cancer was higher in Zurich compared to Ticino, but due to 
a steeper increase in Ticino, the difference was smaller in 2013. Furthermore, the overall trends 
were similar in both cantons with an increase in the early phase of the observed period and a 
decrease in the later phase. Incidence increased until 2002 in Zurich and until 2007 in Ticino 
and decreased thereafter. The time lag in Ticino may be correlated with the different use of 
opportunistic screening. The stratified analyses did not reveal systematic differences between 
the two cantons, except for a different T-stage distribution with a higher proportion of T-stage 
1 cancer cases in Zurich than in Ticino, which may also reflect the different opportunistic 
screening patterns. Further analyses including other Swiss regions and information regarding 
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lifestyle and screening patterns may help to understand the different magnitude in incidence 
rates. 
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Figure Captions 
 
Fig. 1 Age-standardized incidence rates for prostate cancer 1996-2013, Zurich and Ticino (Switzerland). 
TI, Ticino; ZH, Zurich 
 
Fig. 2 Incidence rates of prostate cancer (per 100,000) modelled by joinpoint regression analysis according to age 
group, 1996-2013, Zurich and Ticino (Switzerland). 
 
Fig. 3 Age-standardized incidence rates of prostate cancer (per 100,000) modelled by joinpoint regression analysis 
according to grade, 1996-2013, Zurich and Ticino (Switzerland). 
 
Fig. 4 Age-standardized incidence rates of prostate cancer (per 100,000) modelled by joinpoint regression analysis 
according to T-stage, 1996-2013, Zurich and Ticino (Switzerland). 
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Electronic Supplementary Material Table 1. Prostate cancer incidence in Zurich and Ticino from 1996 to 2013. Number of cases, crude incidence rate (CR), age-standardized 
incidence rate (ASR) per 100,000 (using the 1976 European Standard Population) and age-stratified incidence rates (<65 years, 65-74 years, ≥75 years) 
 Canton of Zurich Canton of Ticino 
Year N population CR ASR <65years 65-74 years ≥75 years N population CR ASR <65 years 65-74 years ≥75 years 
1996 771 572,197 134.7 122.8 28.2 728.6 1182.6 135 145,905 92.5 76.9 22.1 355.1 868.1 
1997 815 574,084 142.0 128.2 33.9 749.5 1172.1 103 145,957 70.6 57.2 7.1 350.8 682.3 
1998 846 576,616 146.7 131.3 35.2 751.0 1219.2 142 146,243 97.1 79.1 22.9 428.6 782.0 
1999 839 581,310 144.3 127.6 39.5 685.2 1173.6 114 146,912 77.6 61.7 18.2 333.6 620.1 
2000 945 587,977 160.7 142.8 46.3 857.2 1106.6 125 147,925 84.5 65.6 15.7 362.8 713.0 
2001 903 595,174 151.7 134.3 50.7 804.9 894.6 148 148,214 99.9 77.0 19.7 451.2 754.5 
2002 1059 603,460 175.5 154.4 59.7 925.0 1011.8 202 149,441 135.2 104.5 44.0 642.5 687.2 
2003 1015 609,422 166.6 145.0 58.4 866.3 934.7 192 150,816 127.3 98.1 43.7 665.4 494.3 
2004 1043 614,922 169.6 146.5 62.5 875.6 891.6 198 152,149 130.1 97.5 44.3 487.5 771.8 
2005 993 621,163 159.9 136.4 62.0 788.5 820.2 216 153,586 140.6 103.2 48.7 594.4 685.1 
2006 1037 627,127 165.4 139.6 60.2 844.3 842.5 214 154,960 138.1 98.4 53.2 455.6 760.1 
2007 1036 636,784 162.7 136.1 61.8 806.4 797.4 285 156,674 181.9 129.8 66.6 683.7 872.1 
2008 1089 650,426 167.4 139.6 59.4 857.8 827.0 271 158,875 170.6 119.9 52.3 751.5 743.3 
2009 1072 662,381 161.8 134.1 56.3 827.4 793.0 241 160,815 149.9 104.4 57.2 545.3 659.9 
2010 1031 671,844 153.5 126.8 55.2 771.3 716.7 224 162,800 137.6 93.9 42.5 557.7 613.5 
2011 1106 683,914 161.7 135.3 60.5 831.0 688.2 254 162,650.5 156.2 105.5 48.7 613.7 694.2 
2012 979 693,449 141.2 116.4 50.1 699.6 655.5 231 164,641.5 140.3 92.6 42.4 540.7 626.9 
2013 916 702,322 130.4 105.1 38.2 682.1 650.6 210 167,159.5 125.6 82.6 39.0 512.9 493.9 
ASR, age-standardized rate; CR, crude rate; N, number 
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Electronic Supplementary Material Table 2. Specific parameters of the joinpoint analyses according to age group, grade and stage 
 Overall trend Trend 1 Joinpoint 1 Trend 2 Joinpoint 2 Trend 3 
 AAPC 95% CI APC 95% CI  APC 95% CI  APC 95% CI 
Zurich           
overall -0.9 -2.1, 0.3 3.1 1.4, 5.0 2002 -1.3 -2.3, -0.3 2011 -10.5 -18.8, -1.2 
<65 years 2.0 0.5, 3.5 13.5 10.9, 16.1 2002 -0.2 -1.3, 1.0 2011 -18.4 -27.5, -8.3 
65-74 years 0.3 -1.0, 1.7 4.1 0.6, 7.8 2002 -1.7 -2.9, -0.5    
≥75 years -3.8 -4.2, -3.3 -3.8 -4.2, -3.3       
Grade 1 -23.9 -27.7, -19.9 -5.0 -9.1, -0.7 2003 -34.8 -40.5, -28.6    
Grade 2 -4.8 -6.7, -2.9 1.6 -0.1, 3.4 2007 -15.6 -19.9, -11.1    
Grade 3 8.3 6.8, 9.8 8.3 6.8, 9.8       
Grade unknown -4.2 -7.9, -0.4 -4.2 -7.9, -0.4       
Stage 1 10.0 6.4, 13.7 10.0 6.4, 13.7       
Stage 2 3.6 0.2, 7.1 15.8 8.6, 23.5 2004 -6.1 -9.7, -2.4    
Stage 3 3.7 2.1, 5.3 3.7 2.1, 5.3       
Stage 4 -2.3 -5.3, 0.9 -2.3 -5.3, 0.9       
Stage unknown -14.7 -17.9, -11.3 -14.7 -17.9, -11.3       
Ticino           
overall 1.9 -0.4, 4.2 6.0 3.3, 8.8 2007 -5.2 -10.1, -0.1    
<65 years 5.5 1.0, 10.1 13.6 7.9, 19.6 2007 -7.9 -16.4, 1.5    
65-74 years 2.4 0.3, 4.6 2.4 0.3, 4.6       
≥75 years -1.2 -2.5, 0.2 -1.2 -2.5, 0.2       
Grade 1 -19.7 -26.6, -12.0 0.3 -10.0, 11.8 2002 -28.8 -38.3, -17.9    
Grade 2 -1.6 -3.5, 0.5 -1.6 -3.5, 0.5       
Grade 3 11.6 7.2, 16.3 21.6 15.0, 28.5 2007 -4.5 -11.5, 3.0    
Grade unknown -5.2 -9.2, -1.1 -5.2 -9.2, -1.1       
Stage 1 19.2 4.9, 35.4 52.0 10.6, 108.9 2002 -13.1 -34.4, 15.0 2007 21.6 8.0, 36.9 
Stage 2 8.0 3.6, 12.6 17.8 11.6, 24.3 2007 -7.8 -15.3, 0.3    
Stage 3 2.6 0.0, 5.3 2.6 0.0, 5.3       
Stage 4 -6.3 -9.4, -3.0 -6.3 -9.4, -3.0       
Stage unknown -9.1 -12.4, -5.7 -2.4 -5.1, 0.4 2007 -20.3 -28.1, -11.7    
APC, annual percent change; AAPC, average annual percent change, 95% CI, 95% confidence interval 
